Here, we examine the impact of SGLT2 inhibition with dapagliflozin on tumor growth in mouse models of obesity-associated cancers: colon adenocarcinoma (MC38 tumors) and triple-negative breast cancer (E0771 tumors), two commonly used murine cancer models whose driver mutations remain under debate and are likely multifactorial, but which robustly express the insulin receptor [6, 36, 48, 49], and demonstrate that dapagliflozin slows tumor growth in both models. This evidence concerns the gene SLC5A2 and neoplasm.